Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 8/20 | 0.61 |
| ▸ | ALKBH5 | Q6P6C2 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | KDM5A | P29375 | 2/20 | 0.61 |
| ▸ | KDM5C | P41229 | 2/20 | 0.61 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.61 |
| ▸ | KDM6B | O15054 | 1/20 | 0.61 |
| ▸ | TET3 | O43151 | 1/20 | 0.61 |
| ▸ | KDM4A | O75164 | 1/20 | 0.61 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | ASPH | Q12797 | 1/20 | 0.61 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.61 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.61 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.61 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.61 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.61 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.61 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2713556 | 0.90 | KDM4E (0.61) | FTOALKBH5KDM4EKDM5AKDM5C | |
| SCHEMBL2714869 | 0.87 | FTO (0.61) | FTOALKBH5KDM4EKDM5AKDM5C | |
| SCHEMBL29831092 | 0.87 | FTO (0.61) | FTOALKBH5KDM4EKDM5AKDM5C | |
| SCHEMBL1028171 | 0.82 | GAA (0.67) | KDM4EALDH1A1MAPTCA1GAA | |
| SCHEMBL4353042 | 0.81 | ITGB3 (0.47) | FTOALKBH5KDM4EKDM5AKDM5C | |
| Acetic Acid SCHEMBL27913808 | 0.80 | GAA (0.61) | KDM4EALDH1A1CA1GAACA9 | |
| SCHEMBL13383551 | 0.80 | KDM4E (0.69) | KDM4EKDM5AKDM5CKDM5BKDM6B | |
| SCHEMBL29382783 | 0.78 | KDM5C (1.00) | FTOALKBH5KDM4EKDM5AKDM5C | |
| SCHEMBL72377 | 0.78 | KDM5C (1.00) | FTOALKBH5KDM4EKDM5AKDM5C | |
| Hydrochloric Acid SCHEMBL10778857 | 0.77 | KDM5C (0.96) | FTOALKBH5KDM4EKDM5AKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362033-B1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-04 | — | — | EP | claimed |
| EP-1362033-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | claimed |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | claimed |
| WO-2002064568-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| EP-1362033-B1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7015237-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-03-21 | — | — | US | disclosed |
| US-6881743-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-04-19 | — | — | US | disclosed |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2004-10-21 | — | — | US | disclosed |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1362033-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | disclosed |
| WO-2002064568-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | FTO 3689/4885ALKBH5 3712/4885KDM4E 476/4885 |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | FTO 3764/4885ALKBH5 2746/4885KDM4E 991/4885 |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | FTO 3650/4885ALKBH5 2556/4885KDM4E 812/4885 |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP13, MMP11, MMP10 | FTO 3527/4885ALKBH5 3617/4885KDM4E 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.